Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.
Manish A. Shah
Consultant or Advisory Role - Genentech
Eric Van Cutsem
Research Funding - Roche
Yoon-Koo Kang
Consultant or Advisory Role - Roche
Honoraria - Roche
Shaker R. Dakhil
No relevant relationships to disclose
Taroh Satoh
Consultant or Advisory Role - Chugai Pharma
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Keisho Chin
No relevant relationships to disclose
Yung-Jue Bang
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Lilian Bu
Employment or Leadership Position - Roche
Grozdana Bilic
Employment or Leadership Position - Roche
Atsushi Ohtsu
Honoraria - Chugai Pharma; Novartis; Roche; Taiho Pharmaceutical